MB
VRDN icon

MPM BioImpact’s Viridian Therapeutics VRDN Stock Holding History

MPM BioImpact’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-649,873
Closed -$12.7M – 44
2026
Q1 		$12.7M Buy
+649,873
New +$19.3M 0.98% 36
2024
Q2 		– Sell
-614,010
Closed -$10.8M – 47
2024
Q1 		$10.8M Buy
614,010
+514,010
+514% +$9.96M 1.73% 22
2023
Q4 		$2.18M Sell
100,000
-155,323
-61% -$2.45M 0.51% 30
2023
Q3 		$3.92M Hold
255,323
– – 1.05% 28
2023
Q2 		$6.07M Buy
+255,323
New +$6.55M 1.22% 26

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MPM BioImpact's VRDN Position: Q2 2026 in Review

MPM BioImpact sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 649,873 shares — an estimated $12.7M sold.

MPM BioImpact first reported a position in VRDN in Q2 2023 and held it in 5 quarters. The position peaked at $12.7M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • MPM BioImpact reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MPM BioImpact sold 649,873 Viridian Therapeutics shares in Q2 2026, an estimated $12.7M.
  • MPM BioImpact first reported a position in Viridian Therapeutics in Q2 2023 and held it in 5 quarters.
  • MPM BioImpact's Viridian Therapeutics position peaked at $12.7M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.